Relmada outlines Phase 3 trial plans for bladder cancer drug NDV-01

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/27/2026

1. SPY
2. AKAM
3. COST
4. META
5. ZS
6. NVDA
7. AWK
8. DRI
9. ULS
10. PRME

Go back to Relmada outlines Phase 3 trial plans for bladder cancer drug NDV-01
(NASDAQ: RLMD) Delayed: 3.83 +0.02 (0.52%)
Previous Close $3.81    52 Week High $4.10 
Open $3.81    52 Week Low $0.87 
Day High $3.87    P/E N/A 
Day Low $3.73    EPS $0.00 
Volume 1,311,049